Please login to the form below

Not currently logged in
Email:
Password:

MedImmune

This page shows the latest MedImmune news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

The deal between AZ’s Medimmune division and the California-based biotech covers the creation and testing of an adeno-associated virus (AAV) based gene therapy, but that’s about all ... This collaboration strategically pairs 4DMT’s expertise in AAV

Latest news

More from news
Approximately 15 fully matching, plus 97 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    Deal Watch March 2017. Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up. ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development. MEDI8897; monoclonal antibody to respiratory

  • Deal Watch October 2016 Deal Watch October 2016

    Licensee / Acquirer. Deal type. Product /technology. Headline $m. Medimmune / AstraZeneca (UK).

  • Deal Watch February 2016 Deal Watch February 2016

    We have seen this for several of the large pharma firms and this month AstraZeneca licensed an antibody developed by MedImmune to start-up company Corvidia Therapeutics concurrently with Corvidia's ... acquisition - corporate. 29.35. AstraZeneca/

  • Pharma deals in August 2015 Pharma deals in August 2015

    MedImmune has paid $27.5m upfront, with a further $700m in milestones and double digit tiered royalties. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐ 3112 vaccine in P1/2 for cervical and head &neck cancer.

  • Pharma deals in February 2015 Pharma deals in February 2015

    platform. This has been rewarded over the years by a string of research alliances with companies including AstraZeneca, MedImmune, Novartis, Takeda and Cubist (now Merck &Co), as well as an extensive

More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest appointments

  • AZ and Medimmune bolsters immuno-oncology leadership AZ and Medimmune bolsters immuno-oncology leadership

    AZ and Medimmune bolsters immuno-oncology leadership. Dr Jean-Charles Soria and Dr Geoffrey Kim join the company. ... AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria,

  • AstraZeneca appoints head of oncology AstraZeneca appoints head of oncology

    AstraZeneca appoints head of oncology. Dr Jamie Freedman joins from AZ subsidiary MedImmune. ... Dr Freedman moves to AstraZeneca from its subsidiary MedImmune, where he was senior vice president of global clinical development, with responsibility for

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • Envigo appoints Patricia Henahan as chief financial officer Envigo appoints Patricia Henahan as chief financial officer

    Henahan brings 15 years of financial experience in the life science sector, including senior leadership roles at AstraZeneca, Eli Lilly and MedImmune.

  • Sanofi appoints Dr Yong-Jun Liu as head of research Sanofi appoints Dr Yong-Jun Liu as head of research

    Sanofi appoints Dr Yong-Jun Liu as head of research. He brings experience from MedImmune and the Baylor Research Institute. ... In January 2014, Dr Liu was appointed head of research at MedImmune, his most recent position.

More from appointments
Approximately 5 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics